Latest Regulatory Filings News

CONNEQT Health has lodged an FDA Pre-Submission for SphygmoCor Cloud, aiming to shift its arterial health analytics from hardware to a scalable software platform with broad commercial potential.

Cynata Therapeutics (ASX: CYP) has had its trading suspension lifted immediately following the publication of results from its Phase 3 Osteoarthritis and Phase 2 Graft versus Host Disease clinical trials.

Toro Energy’s takeover by IsoEnergy has officially become effective following Federal Court approval, setting key dates for share trading suspension and scheme implementation.

CLINUVEL Pharmaceuticals has lodged its Form 20-F with the U.S. SEC, seeking to elevate its American Depository Receipt program to a Nasdaq-listed American Depository Share, aiming to boost visibility and liquidity without raising capital.

Nova Minerals' US holding company shares and warrants are slated to begin trading on NYSE American on 17 June 2026, with ASX trading of CHESS Depositary Interests following on 18 June, marking a key step in the company’s US redomiciliation.

Chariot Resources, through its U.S. subsidiary FMS Lithium Corporation, has significantly expanded its lithium tenure at the Resurgent project in the McDermitt Caldera, staking 573 new claims and nearly doubling its footprint amid improving lithium market conditions.

GCM Corporation is seeking shareholder approval for a 15-to-1 share consolidation as a strategic step towards a potential listing on a US national stock exchange, aiming to boost international capital access and market visibility.

Island Pharmaceuticals has kicked off GMP manufacturing of its antiviral Galidesivir to support late-stage Marburg virus studies under the FDA Animal Rule, marking a key step towards regulatory submission and biodefence readiness.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

Neurizon Therapeutics has gained ethics approval to start a Phase 1 trial of its NUZ-001 oral liquid formulation, aiming to ease treatment for ALS patients with swallowing difficulties.

The Supreme Court of Western Australia has approved the acquisition schemes allowing Li-FT Power to take full ownership of Winsome Resources, with trading suspension on the ASX set for 12 May 2026.

Aurizon reports volume growth across coal, bulk, and container freight for ten months to April, maintaining FY2026 EBITDA and dividend guidance amid a temporary $10 million fuel cost timing hit.